» Articles » PMID: 25224075

Chemotherapy-induced Changes in Cardiac Capillary Permeability Measured by Fluorescent Multiple Indicator Dilution

Overview
Journal Ann Biomed Eng
Date 2014 Sep 17
PMID 25224075
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Anthracyclines cause severe irreversible cardiac toxicity. The study of changes in cardiac permeability with chemotherapy could enhance the understanding of mechanisms behind cardiac damage, and provide useful information to evaluate anthracycline cardiotoxicity. Thirty-six rats (12 Sprague-Dawley, 12 Wistar, 12 Fischer-344) were randomly assigned to control (n = 21) or doxorubicin (n = 15), and injected i.p. with a cumulative dose of 18 mg/kg doxorubicin in saline (vehicle) or vehicle alone over 12 days. Echocardiography was performed at baseline and on day 11. An isolated heart experiment was done on day 12 to obtain perfused heart pressure values, and to measure cardiac capillary permeability using a Texas Red/sodium fluorescein multiple indicator dilution method. Control animals had significantly lower average permeability-surface-area-products (0.035 ± 0.013 cm(3)/s) than doxorubicin animals (0.066 ± 0.023 cm(3)/s), PSP ± SD, p < 0.001. These permeability changes correlated with significant functional changes. There was a significant decline in cardiac function with a deleterious effect of chemotherapy on fractional shortening (p < 0.001), left ventricular developed pressure (p < 0.001), contractility (p < 0.001), and relaxation (p = 0.02). Based on our results, cardiac capillary permeability changes can be detected after in vivo chemotherapy treatment using our fluorescent multiple indicator dilution technique, and may provide valuable information in evaluating cardiotoxicity of novel drugs.

Citing Articles

The Role of MicroRNAs in the Pathogenesis of Doxorubicin-Induced Vascular Remodeling.

Podyacheva E, Snezhkova J, Onopchenko A, Dyachuk V, Toropova Y Int J Mol Sci. 2025; 25(24.

PMID: 39769102 PMC: 11728060. DOI: 10.3390/ijms252413335.


Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells.

Koukorava C, Ahmed K, Almaghrabi S, Pointon A, Haddrick M, Cross M Front Cardiovasc Med. 2024; 11:1372817.

PMID: 39081368 PMC: 11287221. DOI: 10.3389/fcvm.2024.1372817.


Subclinical doxorubicin-induced cardiotoxicity update: role of neutrophils and endothelium.

Todorova V, Wei J, Makhoul I Am J Cancer Res. 2021; 11(9):4070-4091.

PMID: 34659877 PMC: 8493405.


What is considered cardiotoxicity of anthracyclines in animal studies.

Georgiadis N, Tsarouhas K, Rezaee R, Nepka H, Kass G, Dorne J Oncol Rep. 2020; 44(3):798-818.

PMID: 32705236 PMC: 7388356. DOI: 10.3892/or.2020.7688.


Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets.

Fa H, Chang W, Zhang X, Xiao D, Wang J Acta Pharmacol Sin. 2020; 42(4):499-507.

PMID: 32694762 PMC: 8114921. DOI: 10.1038/s41401-020-0471-x.


References
1.
Robert J . Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc Toxicol. 2007; 7(2):135-9. DOI: 10.1007/s12012-007-0022-4. View

2.
Pouna P, Gouverneur G, Tariosse L, Besse P, Robert J . Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol. 1996; 117(7):1593-9. PMC: 1909465. DOI: 10.1111/j.1476-5381.1996.tb15326.x. View

3.
Watson L, Sheth M, Denyer R, Dostal D . Baseline echocardiographic values for adult male rats. J Am Soc Echocardiogr. 2004; 17(2):161-7. DOI: 10.1016/j.echo.2003.10.010. View

4.
Audi S, Linehan J, Krenz G, Dawson C . Accounting for the heterogeneity of capillary transit times in modeling multiple indicator dilution data. Ann Biomed Eng. 1998; 26(6):914-30. DOI: 10.1114/1.138. View

5.
Bassingthwaighte J, Strandell T, DONALD D . Estimation of coronary blood flow by washout of diffusible indicators. Circ Res. 1968; 23(2):259-78. PMC: 2951332. DOI: 10.1161/01.res.23.2.259. View